Cyprotex PLC Enhanced SenCeeTox® technology
October 14 2014 - 2:00AM
RNS Non-Regulatory
TIDMCRX
Cyprotex PLC
14 October 2014
14 October 2014
Cyprotex PLC
Enhanced SenCeeTox(R) technology
for prediction of in vitro skin sensitisation
Cyprotex PLC (AIM: CRX), a specialist ADME-Tox Contract Research
Organisation (CRO), today announces significant advances in its
SenCeeTox(R) model for the prediction of in vitro skin
sensitisation.
SenCeeTox(R) , originally developed by CeeTox in Kalamazoo, was
acquired by Cyprotex when it purchased the business and assets of
CeeTox, Inc. in January 2014. SenCeeTox(R) is an in vitro model
which assesses multiple endpoints to determine general
cytotoxicity, binding of reactive compounds (one of the initial
steps in skin sensitisation) and regulation of genes involved in
skin sensitisation. Cyprotex has utilised its internal expertise in
skin sensitisation and predictive modelling to significantly
improve the predictivity of the SenCeeTox(R) model over the
currently available in vitro approaches. Furthermore, it is one of
the only in vitro models on the market which can accurately predict
skin sensitisation potency for categorising into non/minimal,
moderate, strong and extreme sensitisers in both 2D and 3D cellular
systems.
Within the EU, there has been a complete ban on animal testing
of cosmetics and personal care ingredients and finished products.
This has placed a much greater emphasis on developing alternative
in vitro methods. The majority of cosmetic and personal care
products are applied topically to the skin, and therefore skin
sensitisation is a critical part of the testing strategy before a
product reaches the market. Regulatory guidelines have been drafted
for two in vitro skin sensitisation methods, the Direct Peptide
Reactivity Assay (known as DPRA) and KeratinoSens(TM) , both of
which are offered as services by Cyprotex. However, these single
endpoint assays only define individual mechanisms and do not
categorise skin sensitisation potency. For this reason, the
regulatory authorities recommend a tiered testing strategy using
multiple mechanistic endpoints. SenCeeTox(R) addresses these
concerns by monitoring multiple endpoints from a single incubation,
by providing potency categorisation and exceeding the predictive
capability of both DPRA and KeratinoSens(TM) . An additional
advantage of SenCeeTox(R) is that it can be used either within a 2D
cell-based model or in a 3D skin tissue model. The development of
the 3D model is essential for testing finished products such as
lotions and creams which cannot be applied directly to single
layers of cells.
Commenting on the launch of the improved SenCeeTox(R)
technology, Dr Anthony Baxter, CEO of Cyprotex said: "This improved
SenCeeTox(R) approach provides a robust and accurate method for
assessing skin sensitisation potential which is superior to
existing methods currently recommended by the regulatory
authorities. Cyprotex continues to lead the research in this field
through its expertise in skin science and in silico modelling,
providing cutting edge solutions for our customers."
For further information:
Cyprotex PLC Tel: +44 (0) 1625 505
100
Dr Anthony Baxter, Chief Executive Officer ir@cyprotex.com
John Dootson, Chief Financial Officer www.cyprotex.com
Mark Warburton, Chief Operating Officer
and Legal Counsel
N+1 Singer (Nomad and broker to Cyprotex) Tel: +44 (0)20 7496 3000
Shaun Dobson shaun.dobson@n1singer.com
Jen Boorer jennifer.boorer@n1singer.com
www.n1singer.com
FTI Consulting Tel: +44 (0) 20 3727 1000
Simon Conway cyprotex@fticonsulting.com
Mo Noonan www.fticonsulting.com
Notes to Editors
Cyprotex PLC
Cyprotex is listed on the AIM market of the London Stock
Exchange (CRX). It has sites at Macclesfield and Alderley Park,
both of which are near Manchester in the UK, and at Watertown, MA
and Kalamazoo, MI in the US. The Company was established in 1999
and works with more than 900 partners within the pharmaceutical and
biotech industry, cosmetics and personal care industry and the
chemical industry. Cyprotex acquired Apredica and the assets of
Cellumen Inc. in August 2010 and the combined business provides
support for a wide range of experimental and computational ADME-Tox
and PK services, extending from early drug discovery through to IND
submission. The acquisition of the assets and business of CeeTox in
January 2014 has enabled Cyprotex to expand its range of services
to target the personal care, cosmetics and chemical industries. The
Company's core capabilities include high quality in vitro ADME
screening services, mechanistic toxicology and high content
toxicology screening services, including our proprietary
CellCiphr(R) toxicity prediction technology, predictive modelling
using PBPK and QSAR techniques, including Cloe(R) PK for in vivo PK
prediction, and a range of skin, ocular and endocrine disruption
services. For more information, see www.cyprotex.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAQKNDBPBDDCKD
Cyprotex (LSE:CRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cyprotex (LSE:CRX)
Historical Stock Chart
From Apr 2023 to Apr 2024